BIOSIMILAR DRUGS
TODAY'S HEADLINES
FDA staff recently said a biosimilar rheumatoid arthritis drug was "highly similar" to Johnson & Johnson's leading branded drug, Remicade. Read more |
|
In the latest controversy over hep C drug pricing, the majority of state Medicaid programs cannot afford the leading hep C medications. Read more
|
CONTINUING PHARMACY EDUCATION
This month's CE activity is open for pharmacists and pharmacy technicians, "Part 1: Recognition and referral to enhance recovery: The pharmacist's role in managing opioid use disorder." Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More
|
EDITOR'S PICK
The Biosimilars Forum offers the top 5 things pharmacists should know about biosimilars, including predictions that biosimilars savings could be lower than originally projected. Details
|
|
|
